EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models

Guoqiao Wang iD, Zhaolong Adrian Li iD, Ling Chen, Heather Lugar, Tamara Hershey

PLOS One · 2025

DOI: 10.1371/journal.pone.0321598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Guoqiao Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Wolfram Syndrome, Clinical Trials as Topic, Research Design. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institutes of Health, Snow Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Wolfram syndrome, an ultra-rare condition, currently lacks effective treatment options. The rarity of this disease presents significant challenges in conducting clinical trials, particularly in achieving sufficient statistical power (e.g., 80%). The objective of this study is to propose a novel clinical trial design based on real-world data to reduce the sample size required for conducting clinical trials for Wolfram syndrome.

Methods

We propose a novel clinical trial design with three key features aimed at reducing sample size and improve efficiency: (i) Pooling historical/external controls from a longitudinal observational study conducted by the Washington University Wolfram Research Clinic. (ii) Utilizing run-in data to estimate model parameters. (iii) Simultaneously tracking treatment effects in two endpoints using a multivariate proportional linear mixed effects model.

Results

Comprehensive simulations were conducted based on real-world data obtained through the Wolfram syndrome longitudinal observational study. Our simulations demonstrate that this proposed design can substantially reduce sample size requirements. Specifically, with a bivariate endpoint and the inclusion of run-in data, a sample size of approximately 30 per group can achieve over 80% power, assuming the placebo progression rate remains consistent during both the run-in and randomized periods. In cases where the placebo progression rate varies, the sample size increases to approximately 50 per group.

Conclusions

For rare diseases like Wolfram syndrome, leveraging existing resources such as historical/external controls and run-in data, along with evaluating comprehensive treatment effects using bivariate/multivariate endpoints, can significantly expedite the development of new drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wolfram SyndromeClinical Trials as TopicResearch DesignHumansLongitudinal StudiesSample SizeEndpoint Determination

Autor:innen und Institutionen

  • Department of Neurology, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.
  • Division of Biostatistics, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.
  • Department of Psychiatry, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.
  • Department of Radiology, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.

ORCID-Profile: Guoqiao Wang, Zhaolong Adrian Li

Förderung

  • NICHD NIH HHS
  • National Institutes of Health
  • Snow Foundation
  • American Diabetes Association

Zitieren

APA

Wang, G., Li, Z. A., Chen, L., Lugar, H., & Hershey, T. (2025). Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models. PLOS One. https://doi.org/10.1371/journal.pone.0321598

Vancouver

Wang G, Li ZA, Chen L, Lugar H, Hershey T. Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models. PLOS One. 2025. doi:10.1371/journal.pone.0321598

BibTeX
@article{Wang2025,
  author = {Wang, Guoqiao and Li, Zhaolong Adrian and Chen, Ling and Lugar, Heather and Hershey, Tamara},
  title = {Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0321598}
}
Kostenlos starten →